Publication | Closed Access

Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug

Esophageal CancerDickkopf1-ckap4 PathwayMedicineImmunologyPathologyCell DeathImmune Checkpoint InhibitorTumor SuppressorAnti-ckap4 AntibodyOncologyCancer GrowthCancer ResearchTumor Biology